[12] Patent
[11] Patent No.:GC0004505  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2016                32/2016  
Number of the Decision to Grant the Patent:2016/89121
Date of the Decision to Grant the Patent:06/Dec/2016

[21] Application No.:GCC/P/2007/8874

[22] Filing Date:11/8/2007

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
US
US
PCT
16/5/2004
11/8/2006
30/3/2007
25/7/2007
60/938,410
60/836,996
60/909365
PCT/US 2007/074327

[72] Inventors:1- David R.Langley،2- Van N. Nguyen،3- Rico Lavoie،4- Denis R.St.Laurent،5- Lawrence B. Snyder،6- Edward H. Ruediger،7- Andrew C.Good،8- Fukang Yang،9- Gan Wang،10- Lawrence G. Hamann،11- Makonen Belema،12- Jason Goodrich،13- Omar D. Lopez،14- Nicholas A. Meanwell،15- Clint A. James،16- Carol Bachand،17- Daniel H. Deon،18- Jeffrey Lee Romine،19- Alain Martel

[73] Owner: Bristol-Myers Squibb Holdings Ireland Unlimited Company, Hinterbergstrasse 16, 6312 Steinhausen, Steinhausen, Switzerland

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.: A61K 31/13, 31/4178, 31/427, 31/4745, 31/506, 31/7056, 31/7105, 38/20, 38/21; C07D 403/14, 405/14, 417/14 (2006.01)

[56] Cited Documents:

-WO 2004005264 A2(AXXIMA PHARMACEUTICALS AG) 15 January 2004  
Examiner: PH. Mohammad S. AlMousa

[54] HEPATITIS C VIRUS INHIBITORS
[57] Abstract: The present disclosure vehicles, combinations and methods for the treatment of Hepatitis C virus infection (HCV). Concerns also pharmaceutical compositions containing such compounds and methods of using these compounds in the treatment of HCV infection.
No. of claims: 35


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.